Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
C. B. Eap, G. Gründer, P. Baumann, N. Ansermot, A. Conca, E. Corruble, S. Crettol, M. L. Dahl, J. de Leon, C. Greiner, O. Howes, E. Kim, R. Lanzenberger, J. H. Meyer, R. Moessner, H. Mulder, D. J. Müller, M. Reis, P. Riederer, H. G. Ruhe, O. Spigset, E. Spina, B. Stegman, W. Steimer, J. Stingl, S. Suzen, H. Uchida, S. Unterecker, F. Vandenberghe & C. Hiemke. (2021) Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. The World Journal of Biological Psychiatry 22:8, pages 561-628.
Read now
Read now
Elżbieta Wyska. (2019) Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opinion on Drug Metabolism & Toxicology 15:10, pages 831-847.
Read now
Read now
Igor Nežić, Aleksandra Sander, Ernest Meštrović & Dražen Čavužić. (2019) Production of stable amorphous form by means of spray drying. Particulate Science and Technology 37:5, pages 632-642.
Read now
Read now
Zeyad T. Sahli, Pradeep Banerjee & Frank I. Tarazi. (2016) The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder. Expert Opinion on Drug Discovery 11:5, pages 515-523.
Read now
Read now
Roberto Mandrioli & Laura Mercolini. (2015) Discontinued anxiolytic drugs (2009 – 2014). Expert Opinion on Investigational Drugs 24:4, pages 557-573.
Read now
Read now
William James Deardorff & George T Grossberg. (2014) A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opinion on Pharmacotherapy 15:17, pages 2525-2542.
Read now
Read now
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand & Chi-Un Pae. (2013) A review of current evidence for vilazodone in major depressive disorder. International Journal of Psychiatry in Clinical Practice 17:3, pages 160-169.
Read now
Read now
Jennifer A Reinhold, Laura A Mandos, Falk W. Lohoff & Karl Rickels. (2012) Evidence for the use of vilazodone in the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy 13:15, pages 2215-2224.
Read now
Read now
Articles from other publishers (41)
Weronika Mrozek, Justyna Socha, Klara Sidorowicz, Aleksandra Skrok, Aleksandra Syrytczyk, Iwona Piątkowska-Chmiel & Mariola Herbet. (2023) Pathogenesis and treatment of depression: Role of diet in prevention and therapy. Nutrition 115, pages 112143.
Crossref
Crossref
Zhi-Zheng Wang, Chao Yi, Jun-Jie Huang, Teng-Fei Xu, Kang-Zhi Chen, Zu-Sheng Wang, Ya-Ping Xue, Jie-Lian Lu, Biao Nie, Ying-Jun Zhang, Chuan-Fei Jin & Ge-Fei Hao. (2023) Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter. Journal of Medicinal Chemistry 66:1, pages 371-383.
Crossref
Crossref
Beyzanur ÖZDEMİR, Halil İbrahim ULUSOY, Ümmügülsüm MORGÜL, Marcello LOCATELLİ & Abuzar KABİR. (2022) Sensitive Determination of Venlafaxine in Urine Samples by Using HPLC-DAD System After Fabric Phase Sorptive Extraction. Cumhuriyet Science Journal 43:4, pages 600-605.
Crossref
Crossref
Karanvir Singh, Rohit Bhatia, Bhupinder Kumar, Gurpreet Singh & Vikramdeep Monga. (2022) Design Strategies, Chemistry and Therapeutic Insights of Multi-target
Directed Ligands as Antidepressant Agents. Current Neuropharmacology 20:7, pages 1329-1358.
Crossref
Crossref
Xiaokang Li, Jinwen Li, Yunyuan Huang, Qi Gong, Yan Fu, Yixiang Xu, Junyang Huang, Haolan You, Dong Zhang, Dan Zhang, Fei Mao, Jin Zhu, Huan Wang, Haiyan Zhang & Jian Li. (2022) The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression. European Journal of Medicinal Chemistry 229, pages 114045.
Crossref
Crossref
Tengfei Xu, Yaping Xue, Jielian Lu & Chuanfei Jin. (2021) Synthesis and biological evaluation of 1-(4-(piperazin-1-yl)phenyl)pyridin-2(1H)-one derivatives as potential SSRIs. European Journal of Medicinal Chemistry 223, pages 113644.
Crossref
Crossref
Somayyeh Heydari, Davood Habibi, Ali Reza Faraji, Hassan keypour & Masoumeh Mahmoudabadi. (2021) An overview on the progress and development on the palladium catalyzed direct cyanation. Inorganica Chimica Acta 514, pages 119956.
Crossref
Crossref
Sagar R. Mudshinge, Chinmay S. Potnis, Bo Xu & Gerald B. Hammond. (2020) HCl·DMPU-assisted one-pot and metal-free conversion of aldehydes to nitriles. Green Chemistry 22:13, pages 4161-4164.
Crossref
Crossref
Hesham Y Elnazer & David S Baldwin. (2020) Structured review of the use of the Arizona sexual experiences scale in clinical settings. Human Psychopharmacology: Clinical and Experimental 35:3.
Crossref
Crossref
Yang Zhang, Guoxun Zheng, Tingting Fu, Jiajun Hong, Fengcheng Li, Xiaojun Yao, Weiwei Xue & Feng Zhu. (2020) The binding mode of vilazodone in the human serotonin transporter elucidated by ligand docking and molecular dynamics simulations. Physical Chemistry Chemical Physics 22:9, pages 5132-5144.
Crossref
Crossref
Cheng Cui, Huanhuan Wang, Zhenlei Wang, Ji Jiang, Ni Wu, Binglin Cui, Quanming Zhang, Qian Zhao & Pei Hu. (2019) An ultra HPLC–MS/MS method for quantification of hypidone hydrochloride (YL-0919) and application to a pharmacokinetic study. Bioanalysis 11:13, pages 1243-1254.
Crossref
Crossref
Yu-hua Ran, Xiao-xu Hu, Yu-lu Wang, Nan Zhao, Li-ming Zhang, Hua-xia Liu & Yun-feng Li. (2017) YL-0919, a dual 5-HT1A partial agonist and SSRI, produces antidepressant- and anxiolytic-like effects in rats subjected to chronic unpredictable stress. Acta Pharmacologica Sinica 39:1, pages 12-23.
Crossref
Crossref
Xiaokang Li, Huan Wang, Yixiang Xu, Wenwen Liu, Qi Gong, Wei Wang, Xiaoxia Qiu, Jin Zhu, Fei Mao, Haiyan Zhang & Jian Li. (2017) Novel Vilazodone–Tacrine Hybrids as Potential Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease Accompanied with Depression: Design, Synthesis, and Biological Evaluation. ACS Chemical Neuroscience 8:12, pages 2708-2721.
Crossref
Crossref
Balasaheb B. Chavan, Pradipbhai D. Kalariya, Shristy Tiwari, Rakesh D. Nimbalkar, Prabha Garg, R. Srinivas & M.V.N. Kumar Talluri. (2017) Identification and characterization of vilazodone metabolites in rats and microsomes by ultrahigh-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Communications in Mass Spectrometry 31:23, pages 1974-1984.
Crossref
Crossref
Gerard J. Marek. 2017. Drug Selectivity. Drug Selectivity
335
367
.
Patrick R. Finley, Jennifer Le & Kelly C. Lee. 2016. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
205
245
.
Clara Grosso. 2016. Herbal Medicine in Depression. Herbal Medicine in Depression
557
571
.
Arif Khan & Walter A. Brown. (2015) Antidepressants versus placebo in major depression: an overview. World Psychiatry 14:3, pages 294-300.
Crossref
Crossref
Sheng-Min WangChangsu HanSoo-Jung LeeAshwin A PatkarPrakash S MasandChi-Un Pae. (2015) Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action. Psychiatry Investigation 12:2, pages 155.
Crossref
Crossref
Wenwen Sui, Xiaojing Yang, Wenhong Yu, Yi Jin, Xinyi Luan, Xiangjun Wang & Haiyan Xu. (2014) A validated LC–MS/MS method for the rapid quantification of vilazodone in rat plasma: Application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 98, pages 228-234.
Crossref
Crossref
Jeremy D. Coplan, Srinath Gopinath, Chadi G. Abdallah & Benjamin R. Berry. (2014) A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy. Frontiers in Behavioral Neuroscience 8.
Crossref
Crossref
Christoph van Amsterdam & Christoph A. Seyfried. (2014) Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output. Psychopharmacology.
Crossref
Crossref
Hong-xia Chen, Zeng-liang Jin, Li-ming Zhang, Rui Xue, Xiao-dan Xu, Nan Zhao, Zhi-kun Qiu, Xian-wang Wang, You-zhi Zhang, Ri-fang Yang & Yun-feng Li. (2013) Antidepressant-Like Activity of YL-0919: A Novel Combined Selective Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist. PLoS ONE 8:12, pages e83271.
Crossref
Crossref
Abimbola Farinde. (2013) Vilazodone: A landmark antidepressant approval or another “me-too” drug?. Mental Health Clinician 3:4, pages 193-197.
Crossref
Crossref
Charles R. AshbyJr.Jr., John H. Kehne, Gerd D. Bartoszyk, Matthew J. Renda, Maria Athanasiou, Kerri A. Pierz & Christoph A. Seyfried. (2013) Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor. European Journal of Pharmacology 714:1-3, pages 359-365.
Crossref
Crossref
Elliott Richelson. (2013) Multi-modality: a new approach for the treatment of major depressive disorder. International Journal of Neuropsychopharmacology 16:6, pages 1433-1442.
Crossref
Crossref
Ramesh Boinpally, Harry Alcorn, Marijke H. Adams, James Longstreth & John Edwards. (2013) Pharmacokinetics of Vilazodone in Patients with Mild or Moderate Renal Impairment. Clinical Drug Investigation 33:3, pages 199-206.
Crossref
Crossref
David R. P. Guay. (2012) Vilazodone Hydrochloride, a Combined SSRI and 5-HT1A Receptor Agonist for Major Depressive Disordersts. The Consultant Pharmacist 27:12, pages 857-867.
Crossref
Crossref
Alexandra Wendler & Martin Wehling. (2012) Translatability scoring in drug development: eight case studies. Journal of Translational Medicine 10:1.
Crossref
Crossref
Maryam Iranikhah, Terri M. Wensel & Angela R. Thomason. (2012) Vilazodone for the Treatment of Major Depressive Disorder. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32:10, pages 958-965.
Crossref
Crossref
Elizabeth Choi, Monika Zmarlicka & Megan J. Ehret. (2012) Vilazodone: A novel antidepressant. American Journal of Health-System Pharmacy 69:18, pages 1551-1557.
Crossref
Crossref
Min-Soo Han, Young-Hue Han, Chi-Man Song & Hoh-Gyu Hahn. (2012) The Design and Synthesis of 1,4-Substituted Piperazine Derivatives as Triple Reuptake Inhibitors. Bulletin of the Korean Chemical Society 33:8, pages 2597-2602.
Crossref
Crossref
Xue Y. Zhu, Jagan R. Etukala, Suresh V.K. Eyunni, Vincent Setola, Bryan L. Roth & Seth Y. Ablordeppey. (2012) Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants. European Journal of Medicinal Chemistry 53, pages 124-132.
Crossref
Crossref
Dan J SteinMichael Van AmeringenBeth PattersonElizabeth Lee. 2012. Antidepressants and Major Depressive Disorder. Antidepressants and Major Depressive Disorder
26
47
.
Mohammed Shahid. 2012. Designing Multi-Target Drugs. Designing Multi-Target Drugs
14
31
.
Tammy J. LindsayKirsten VitrikasMichael TemporalChristopher M. Herndon. (2012) Diabetic Neuropathic Pain: Real World Treatment Options. Clinical Medicine Insights: Therapeutics 4, pages CMT.S7266.
Crossref
Crossref
Edoardo Spina, Gianluca Trifirò & Filippo Caraci. (2012) Clinically Significant Drug Interactions with Newer Antidepressants. CNS Drugs 26:1, pages 39-67.
Crossref
Crossref
James E. Frampton. (2011) Vilazodone. CNS Drugs 25:7, pages 615-627.
Crossref
Crossref
Wesley T Lindsey. (2011) Vilazodone for the Treatment of Depression. Annals of Pharmacotherapy 45:7-8, pages 946-953.
Crossref
Crossref
Robert H. Howland. (2011) Vilazodone. Journal of Psychosocial Nursing and Mental Health Services 49:3, pages 19-22.
Crossref
Crossref
Fraser F. Fleming, Lihua Yao, P. C. Ravikumar, Lee Funk & Brian C. Shook. (2010) Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore. Journal of Medicinal Chemistry 53:22, pages 7902-7917.
Crossref
Crossref